Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MNPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMonopar presents Phase 2 Wilson disease trial results at major European liver conference
Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
medium
Monopar presented Phase 2 study results for ALXN1840 (tiomolibdate choline) in Wilson disease patients at EASL International Liver Congress 2026, evaluating effects on liver pathology and clinical symptoms.
Item 8.01 view on EDGAR → -
medium
The study (NCT04422431) represents a key clinical milestone for the company's lead Wilson disease program, though specific efficacy and safety data are contained in the attached presentation rather than the filing itself.
8-K body view on EDGAR → -
low
Company filed presentation slides as Exhibit 99.1, which would contain the actual trial data and conclusions from the EASL conference.
Exhibit 99.1 view on EDGAR →
Summary
Monopar Therapeutics disclosed that it presented Phase 2 clinical trial results for ALXN1840, its Wilson disease drug candidate, at the European Association for the Study of the Liver's International Liver Congress on May 29, 2026. The study evaluated the drug's effect on liver pathology and clinical symptoms in Wilson disease patients, a rare genetic disorder causing copper accumulation in organs.
While the 8-K confirms the presentation occurred at a prestigious European medical conference, the actual trial data and outcomes are contained in the attached presentation slides rather than summarized in the filing itself. For retail investors, this represents a clinical development milestone that could validate or challenge the drug's therapeutic potential.
Wilson disease is a rare disease indication, which typically means smaller patient populations but potentially less competition and regulatory advantages. The key follow-on item is to review the actual presentation slides (Exhibit 99.1) for efficacy data, safety profile, and any commentary on the path to Phase 3 trials or regulatory discussions. Investor focus should be on whether the results support continued development and potential partnership or commercialization opportunities.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 29, 2026, Monopar Therapeutics Inc. (“Monopar”) presented results from a Phase 2 study (NCT04422431) evaluating the effect of ALXN1840 (tiomolibdate choline) on liver pathology and clinical symptoms in patients with Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2026.
Monopar disclosed presentation of Phase 2 clinical trial results for ALXN1840, a drug candidate targeting Wilson disease, at a major European liver disease conference. The study evaluated effects on liver pathology and clinical symptoms. Actual study results are contained in the attached exhibit.
Event · Item 9.01 — Financial Statements and Exhibits
Monopar filed an 8-K attaching a presentation dated May 29, 2026, with no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1
Presentation dated May 29, 2026.
The company attached a presentation dated May 29, 2026 as Exhibit 99.1. The 8-K body does not describe the presentation's content or purpose, making it impossible to assess materiality from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify